arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

FILANA THERAPEUTICS, INC.

FLNA
$0.98 ▲ +0.03 (+2.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

FILANA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $47.3M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -101.3%
FCF / Share $-0.68
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$41.12M
↑ +277.6%
Net Income Profit after all expenses
$-90.97M
↓ -273.7%
Operating Margin Operating profit as % of sales
76.3%
↑ +313.2%
FCF / Share Free cash flow per share
$-0.68
↑ +73.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters